Pricing Log in Create free account

Jupiter Neurosciences, Inc. (JUNS) vs Liminatus Pharma Inc. (LIMN)

Jupiter Neurosciences, Inc. and Liminatus Pharma Inc. are both Biotechnology companies. Jupiter Neurosciences, Inc. and Liminatus Pharma Inc. are of similar size ($4.3M and $4.1M). Across the 8 metrics below, Liminatus Pharma Inc. leads on 5 and Jupiter Neurosciences, Inc. on 3.

Valuation

Metric JUNS LIMN Biotechnology median
P/E n/m n/m 8.50
P/S n/m n/m 9.71
P/B n/m 9.79 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m n/m 9.21
Earnings yield (656.97%) (773.03%) (33.15%)
Free cash flow yield (446.77%) (135.00%) (25.50%)

Profitability

Metric JUNS LIMN Biotechnology median
Gross margin — — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (1,888.80%) 294.43% (56.36%)
Return on assets (239.36%) (471.47%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric JUNS LIMN Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) (212.50%) (112.19%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric JUNS LIMN Biotechnology median
Debt to equity 0.00 4.80 0.00
Current ratio 0.66 1.12 4.72
Net debt to EBITDA 0.43 (0.37) 0.96

Dividend

Metric JUNS LIMN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric JUNS LIMN Biotechnology median
Market cap 4.14m 4.32m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack